Home

search

Subjectguide
Journals
Books / Serials / Multimedia
Services
Services

Login for Subscribers
Logout

Sitemap
Help
Contacts


Logo






Vol. 24, No. 1, 2007   

Free Abstract     Article (References)     Article (PDF 477 KB)     
Free Access

Review Article

Is Antioxidant Therapy a Viable Alternative for Mild Cognitive Impairment? Examination of the Evidence
Marie-Laure Ancelina, Yves Christenb, Karen Ritchiea

aInserm, U888, University of Montpellier-1, Montpellier, and
bIpsen, Paris, France

Address of Corresponding Author

Dement Geriatr Cogn Disord 2007;24:1-19 (DOI: 10.1159/000102567)


 goto top of page Key Words

  • Oxidative stress
  • Antioxidants
  • Vitamins
  • Ginkgo biloba
  • Mild cognitive impairment
  • Alzheimer's disease

 goto top of page Abstract

Therapeutic interventions for the prodromal stages of dementia are currently being sought with a view to delaying if not preventing disease onset. Uncertainty as to whether cognitive disorder in a given individual will progress towards dementia and adverse drug side effects has led to hesitancy on the part of drug regulators to instigate preventive pharmacotherapies. In this context, antioxidant therapies may provide a low-risk alternative, targeting very early biological changes. While a growing body of knowledge demonstrates both the importance of oxidative stress in the aetiology of dementia and the efficacy of antioxidant treatment in animal and cellular models, studies in humans are presently inconclusive. While some antioxidants, notably flavonoid- or vitamin-rich diets, appear to lower the relative risk for Alzheimer's disease in humans in observational studies, these results must be interpreted in the light of the biological complexity of the relationship between oxidative stress and neurodegeneration, and the methodological and theoretical shortcomings of studies conducted to date. A clearer understanding of these factors will assist in the interpretation of the results of the intervention studies which are now being undertaken; these studies being the only current means of establishing efficacy for preventive drug treatment of Alzheimer's disease.

Copyright © 2007 S. Karger AG, Basel


 goto top of page Author Contacts

Dr. Yves Christen
24 rue Erlanger
FR-75016 Paris (France)
Tel. +33 144 96 1010, Fax +33 144 96 1199 E-Mail yves.christen@ipsen.com


 goto top of page Article Information

Y.C. is an employee of Ipsen.

Accepted: January 18, 2007
Published online: May 10, 2007
Number of Print Pages : 19
Number of Figures : 0, Number of Tables : 2, Number of References : 188

 
Journal Home
Journal Content
Guidelines
Editorial Board
Aims and Scope
Subscriptions
Medline Abstract (ID 17495472)
Download Citation
Cited In



This journal is part of the first subject package of the Karger

Journal Archive Collection

Information on packages (PDF)
Free sample issues


For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.




copyright  © 2009 S. Karger AG, Basel